A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
En randomiseret, dobbeltmaskeret, multicenter, 3-arm pivotal fase 2/3-undersøgelse til evaluering af effektiviteten og sikkerheden af Intravitreal EYE103 sammenlignet med Intravitreal Ranibizumab (0,5 mg) hos deltagere med diabetisk makulaødem
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
CABA, Argentina, 1023
- Buenos Aires, Argentina
-
Córdoba, Argentina, X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, 1015
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, 1120
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, C1033AAW
- Buenos Aires, Argentina
-
Caba, Buenos Aires, Argentina, C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario, Sante Fe, Argentina, 2000
- Santa Fe, Argentina
-
-
-
-
-
Albury, Australien, 2640
- Albury, Australia
-
Parramatta, Australien, 2150
- Parramatta, Australia
-
Sydney, Australien, 2000
- Sydney, Australia
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2000
- Sydney Retina Clinic
-
Sydney, New South Wales, Australien, 2135
- Sydney, Australia
-
-
-
-
-
Medellín, Colombia, 50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá, Columbia, Colombia, 110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760042
- Cali, Colombia
-
-
-
-
-
Bradford, Det Forenede Kongerige, BD9 6RJ
- Bradford, United Kingdom
-
Bristol, Det Forenede Kongerige, BS1 2LX
- Bristol, UK
-
Liverpool, Det Forenede Kongerige, L7 8YA
- Liverpool, United Kingdom
-
Sunderland, Det Forenede Kongerige, SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton, Det Forenede Kongerige, WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London, Middlesex, Det Forenede Kongerige, NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York, UnitedKingdom, Det Forenede Kongerige, YO10 4DZ
- York, United Kingdom
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85255
- Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, Forenede Stater, 72703
- Fayetteville, Arkansas
-
Springdale, Arkansas, Forenede Stater, 72764
- Springdale, Arkansas
-
-
California
-
Bakersfield, California, Forenede Stater, 93309
- Bakersfield, CA
-
Glendale, California, Forenede Stater, 91204
- Glendale, CA
-
Modesto, California, Forenede Stater, 95356
- Modesto, CA
-
Mountain View, California, Forenede Stater, 94040
- Mountain View, CA
-
Redlands, California, Forenede Stater, 92374
- Redlands, CA
-
Sacramento, California, Forenede Stater, 95825
- Sacramento, CA
-
Sacramento, California, Forenede Stater, 95841
- Sacramento, CA
-
Santa Ana, California, Forenede Stater, 92705
- Santa Ana
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80909
- Colorado Springs, CO
-
Denver, Colorado, Forenede Stater, 80210
- Denver, Colorado
-
-
Connecticut
-
Danbury, Connecticut, Forenede Stater, 06810
- Danbury, CT
-
Manchester, Connecticut, Forenede Stater, 06042
- Manchester, CT
-
Waterford, Connecticut, Forenede Stater, 06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach, Florida, Forenede Stater, 33064
- Deerfield Beach, FL
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- Fort Lauderdale, FL
-
Fort Myers, Florida, Forenede Stater, 33912
- Fort Myers,FL
-
Gainesville, Florida, Forenede Stater, 32607
- Gainesville, FL
-
Orlando, Florida, Forenede Stater, 32806
- Orlando, Florida
-
Plantation, Florida, Forenede Stater, 33324
- Plantation, FL
-
Sarasota, Florida, Forenede Stater, 34232
- Sarasota, FL
-
St. Petersburg, Florida, Forenede Stater, 33711
- Saint Petersburg, FL
-
Tallahassee, Florida, Forenede Stater, 32308
- Tallahassee, FL
-
Tampa, Florida, Forenede Stater, 33609-4614
- Tampa, FL
-
Tampa, Florida, Forenede Stater, 33617
- Tampa, FL
-
Winter Haven, Florida, Forenede Stater, 33880
- Winter Haven, FL
-
-
Illinois
-
Lemont, Illinois, Forenede Stater, 60439
- Lemont, IL
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines, Iowa, Forenede Stater, 50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa, Kansas, Forenede Stater, 66215
- Lenexa, Kansas
-
Wichita, Kansas, Forenede Stater, 67214
- Wichita, Kansas
-
-
Maine
-
Portland, Maine, Forenede Stater, 04101
- Portland, Maine
-
-
Maryland
-
Hagerstown, Maryland, Forenede Stater, 21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield, Massachusetts, Forenede Stater, 01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55435
- Minneapolis, MN
-
-
Mississippi
-
Madison, Mississippi, Forenede Stater, 39110
- Madison, MS
-
-
New Jersey
-
Bloomfield, New Jersey, Forenede Stater, 07003
- Bloomfield, NJ
-
Cherry Hill, New Jersey, Forenede Stater, 08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool, New York, Forenede Stater, 13088
- Liverpool, NY
-
Oceanside, New York, Forenede Stater, 11572
- Oceanside, NY
-
Rochester, New York, Forenede Stater, 14620
- Rochester, NY
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28803
- Asheville, NC
-
Hickory, North Carolina, Forenede Stater, 28602
- Hickory, NC
-
Wake Forest, North Carolina, Forenede Stater, 27587
- Wake Forest, MC
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44122
- Cleveland, Ohio
-
Cleveland, Ohio, Forenede Stater, 44130
- Cleveland, OH
-
Youngstown, Ohio, Forenede Stater, 44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond, Oklahoma, Forenede Stater, 73013
- Edmond, OK
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97221
- Portland, OR
-
Springfield, Oregon, Forenede Stater, 97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forenede Stater, 18017
- Bethlehem, PA
-
Erie, Pennsylvania, Forenede Stater, 16507
- Erie, PA
-
-
South Carolina
-
Beaufort, South Carolina, Forenede Stater, 29902
- Beaufort, SC
-
Florence, South Carolina, Forenede Stater, 29501
- Florence, SC
-
Ladson, South Carolina, Forenede Stater, 29456
- Ladson, SC
-
West Columbia, South Carolina, Forenede Stater, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Germantown, TN
-
Hixson, Tennessee, Forenede Stater, 37343
- Hixson, Tennessee
-
Johnson City, Tennessee, Forenede Stater, 37604
- Johnson City, Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37922
- Knoxville, TN
-
Nashville, Tennessee, Forenede Stater, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, Forenede Stater, 79606
- Abilene, TX
-
Amarillo, Texas, Forenede Stater, 79109
- Amarillo, TX
-
Amarillo, Texas, Forenede Stater, 79106
- Amarillo, TX
-
Arlington, Texas, Forenede Stater, 76012
- Arlington, TX
-
Austin, Texas, Forenede Stater, 78705
- Austin, TX
-
Beaumont, Texas, Forenede Stater, 77707
- Beaumont, TX
-
Bellaire, Texas, Forenede Stater, 77401
- Bellaire, TX
-
Dallas, Texas, Forenede Stater, 75231
- Dallas, TX
-
Fort Worth, Texas, Forenede Stater, 76104
- Fort Worth, TX
-
Katy, Texas, Forenede Stater, 77494
- Katy, TX
-
Plano, Texas, Forenede Stater, 75075
- Plano, TX
-
Round Rock, Texas, Forenede Stater, 78681
- Round Rock, TX
-
San Antonio, Texas, Forenede Stater, 78240
- San Antonio, TX
-
Schertz, Texas, Forenede Stater, 78154
- Schertz, Texas
-
The Woodlands, Texas, Forenede Stater, 77384
- The Woodlands, TX
-
Willow Park, Texas, Forenede Stater, 76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg, Virginia, Forenede Stater, 24502
- Lynchburg, VA
-
Richmond, Virginia, Forenede Stater, 23235
- Richmond, Virginia
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99204
- Spokane, WA
-
-
-
-
-
Créteil, Frankrig, 94010
- Creteil, France
-
Lyon, Frankrig, 69004
- Lyon, France
-
Marseille, Frankrig, 13008
- Marseille, France
-
Paris, Frankrig, 75006
- Paris, France
-
Paris, Frankrig, 75015
- Paris, France
-
Paris, Frankrig, 75019
- Paris, France
-
Saint-Cyr-sur-Loire, Frankrig, 37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon, Cedex, Frankrig, 21079
- Cedex, France
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Beer Yakov, Israel
-
Haifa, Israel, 3436212
- Haifa, Israel
-
Jerusalem, Israel, 9112001
- Jerusalem, Israel
-
Petah Tikva, Israel, 49100
- Petah Tikva, Israel
-
Rehovot, Israel, 76100
- Rehovot, Israel
-
Tel Aviv, Israel, 6423906
- Tel Aviv, Israel
-
-
-
-
-
Bologna, Italien, 40138
- Bologna, Italy
-
Florence, Italien, 50139
- Firenze, Italy
-
Milan, Italien, 20122
- Milano, Italy
-
Milan, Italien, 20132
- Milano, Italy
-
Milan, Italien, 20157
- Milano, Italy
-
Roma, Italien, 00168
- Roma, Italy
-
Rome, Italien, 81.00133
- Rome, Italy
-
Udine, Italien, 33100
- Udine, Italy
-
-
-
-
-
Osijek, Kroatien, 31000
- Osijek, Croatia
-
-
-
-
-
Riga, Letland, LV1002
- Riga, Latvia
-
Riga, Letland, LV1006
- Riga, Latvia
-
-
-
-
-
Bialystok, Polen, 15-866
- Bialystok, Poland
-
Bydgoszcz, Polen, 85-309
- Bydgoszcz, Poland
-
Bydgoszcz, Polen, 85-631
- Bydgoszcz, Poland
-
Gdansk, Polen, 80-809
- Gdansk, Poland
-
Katowice, Polen, 40-594
- Katowice, Poland
-
Krakow, Polen, 31-501
- Krakow, Poland
-
Olsztyn, Polen, 10-424
- Olsztyn, Poland
-
Tarnowskie Góry, Polen, 42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk, Gdansk, Polen, 80-809
- Gdansk, Poland
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Coimbra, Portugal
-
Coimbra, Portugal, 3030-163
- Coimbra, Portugal
-
Porto, Portugal, 4200-319
- Porto, Portugal
-
-
-
-
PR
-
Arecibo, PR, Puerto Rico, 00612
- Arecibo, PR
-
-
-
-
-
Trebišov, Slovakiet, 075 01
- Trebisov, Slovakia
-
Trenčín, Slovakiet, 911 01
- Trencin, Slovakia
-
Žilina, Slovakiet, 012 07
- Zilina, Slovakia
-
-
-
-
-
Barcelona, Spanien, 08035
- Barcelona, Spain
-
Barcelona, Spanien, 08021
- Barcelona, Spain
-
Barcelona, Spanien, 08022
- Barcelona, Spain
-
Barcelona, Spanien, 08195
- Barcelona, Spain
-
Santiago de Compostela, Spanien, 15706
- Santiago de Compostela, Spain
-
Seville, Spanien, 41009
- Sevilla, Spain
-
Zaragoza, Spanien, 50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot, Valencia, Spanien, 46100
- Valencia, Spain
-
-
-
-
-
Mladá Boleslav, Tjekkiet, 293 01
- Mlada Boleslav, Czechia
-
Náchod, Tjekkiet, 547 01
- Nachod, Czechia
-
Prague, Tjekkiet, 1150/50
- Prague, Czechia
-
Prague, Tjekkiet
- Prague, Czechia
-
-
-
-
Turkey
-
Ankara, Turkey, Tyrkiet (Türkiye), 06230
- Ankara, Turkey
-
Ankara, Turkey, Tyrkiet (Türkiye), 06490
- Ankara, Turkey
-
Balçova, Turkey, Tyrkiet (Türkiye), 35330
- Balcova, Turkey
-
-
-
-
-
Frankfurt, Tyskland, 60590
- Frankfurt, Germany
-
Hanover, Tyskland, 30625
- Hanover, Germany
-
München, Tyskland, 80336
- Munchen, Germany
-
Münster, Tyskland, 48145
- Munster, Germany
-
-
-
-
-
Budapest, Ungarn, H-1062
- Budapest, Hungary
-
Budapest, Ungarn, H-1085
- Budapest, Hungary
-
Budapest, Ungarn, H-1106
- Budapest, Hungary
-
Budapest, Ungarn, H-1133
- Budapest, Hungry
-
Debrecen, Ungarn, H-4032
- Debrecen, Hungary
-
Pécs, Ungarn, H-7621
- Pecs, Hungary
-
Szeged, Ungarn, H-6720
- Szeged, Hungary
-
Zalaegerszeg, Ungarn, 8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Graz, Østrig, 8036
- Graz, Austria
-
Innsbruck, Østrig, 6020
- Innsbruck, Austria
-
Vienna, Østrig, 1090
- Vienna, Austria
-
Vienna, Østrig, 1140
- Vienna, Austria
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Andre navne:
|
|
Eksperimentel: Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Andre navne:
|
|
Aktiv komparator: Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Tidsramme: Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Tidsramme: Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Tidsramme: Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
Tidsramme: Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
Tidsramme: Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Tidsramme: Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Tidsramme: Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Tidsramme: Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Tidsramme: Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Tidsramme: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Tidsramme: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Tidsramme: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Charles Miller, MD PhD, EyeBiotech Ltd.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- EYE-RES-102
- MK-3000-001 (Anden identifikator: MSD)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .